We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in ...

Truist analyst Joon Lee lowered the firm’s price target on Arvinas (ARVN) to $21 from $65 and keeps a Buy rating on the shares as part of a ...

HC Wainwright restated their buy rating on shares of Arvinas (NASDAQ:ARVN – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $81.00 price ...

Piper Sandler lowered the firm’s price target on Arvinas (ARVN) to $24 from $67 on narrowed vepdegestrant ESR1-mutant mBC approval, while ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports. Five ...

Arvinas is continuing its investigation of arv-102 in neurodegenerative diseases associated with lrrk2 and lysosome ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

According to TipRanks.com, Risinger is a 5-star analyst with an average return of 8.5% and a 54.1% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure ...

March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today ...

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...